Followers | 1321 |
Posts | 26908 |
Boards Moderated | 6 |
Alias Born | 12/10/2012 |
Thursday, March 30, 2023 10:34:11 AM
And now its up to $43
Looks like the iHUB people are shutting down my board again like previous..... and I'm running out of free posts.
This one started trading today and now its my SECOND time opening up this board. WHAT GIVES ??
https://www.apollomicsinc.com/
GO $APLM
Recent APLM News
- Apollomics Announces Private Placement Financing and Addition to Board of Directors • GlobeNewswire Inc. • 05/08/2024 08:05:00 PM
- Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene • GlobeNewswire Inc. • 04/25/2024 12:30:00 PM
- Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting • GlobeNewswire Inc. • 04/10/2024 11:00:00 AM
- Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting • GlobeNewswire Inc. • 04/02/2024 12:00:00 PM
- Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 11:00:00 AM
- Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024 • GlobeNewswire Inc. • 03/26/2024 12:00:00 PM
- Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer • GlobeNewswire Inc. • 03/04/2024 12:00:00 PM
- Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/07/2024 12:00:00 PM
- Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency • GlobeNewswire Inc. • 01/19/2024 09:15:00 PM
- Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference • GlobeNewswire Inc. • 01/17/2024 09:30:00 PM
- Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- Apollomics to Present at the 2024 Biotech Showcase • GlobeNewswire Inc. • 01/02/2024 09:30:23 PM
- Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation • GlobeNewswire Inc. • 12/04/2023 12:00:00 PM
- Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference • GlobeNewswire Inc. • 11/29/2023 12:30:00 PM
- Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC) • GlobeNewswire Inc. • 11/28/2023 12:00:40 PM
- Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 11/16/2023 01:30:00 PM
- Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation • GlobeNewswire Inc. • 10/31/2023 12:30:06 PM
- Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion • GlobeNewswire Inc. • 10/26/2023 12:50:02 PM
- Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75% • GlobeNewswire Inc. • 10/23/2023 12:30:21 PM
- Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023 • GlobeNewswire Inc. • 10/16/2023 10:55:05 PM
- Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 09/28/2023 08:17:57 PM
- Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 09/06/2023 11:00:00 AM
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM